1500TiPeXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. (23rd October 2018) - Horn, L; Wu, Y-L; Reck, M; Wakelee, H; Liang, C; Harrow, K; Oertel, V; Mok, T